Wall Street analysts predict that Nevro Corp (NYSE:NVRO) will report ($0.29) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Nevro’s earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.56). Nevro reported earnings per share of ($0.21) in the same quarter last year, which suggests a negative year-over-year growth rate of 38.1%. The company is expected to announce its next quarterly earnings report on Monday, November 5th.
According to Zacks, analysts expect that Nevro will report full-year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($2.22) to ($0.95). For the next financial year, analysts expect that the company will post earnings of ($0.50) per share, with EPS estimates ranging from ($1.05) to $0.19. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Nevro.
Nevro (NYSE:NVRO) last issued its quarterly earnings data on Thursday, August 2nd. The medical equipment provider reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). The firm had revenue of $96.10 million for the quarter, compared to analysts’ expectations of $96.10 million. Nevro had a negative net margin of 10.68% and a negative return on equity of 15.84%. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.40) EPS.
Shares of Nevro stock traded up $0.72 during trading on Friday, reaching $64.23. 404,807 shares of the stock traded hands, compared to its average volume of 1,641,840. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -51.38 and a beta of -0.83. Nevro has a 52-week low of $35.41 and a 52-week high of $94.34. The company has a quick ratio of 6.29, a current ratio of 8.06 and a debt-to-equity ratio of 0.61.
In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of Nevro stock in a transaction on Monday, May 14th. The shares were sold at an average price of $76.14, for a total value of $532,980.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.90% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Advisors LLC acquired a new position in Nevro during the fourth quarter valued at $900,000. Kornitzer Capital Management Inc. KS raised its position in shares of Nevro by 12.0% in the first quarter. Kornitzer Capital Management Inc. KS now owns 620,813 shares of the medical equipment provider’s stock worth $53,806,000 after acquiring an additional 66,530 shares during the period. SG Americas Securities LLC acquired a new position in shares of Nevro in the first quarter worth about $208,000. American Century Companies Inc. raised its position in shares of Nevro by 24.5% in the first quarter. American Century Companies Inc. now owns 100,672 shares of the medical equipment provider’s stock worth $8,725,000 after acquiring an additional 19,818 shares during the period. Finally, Victory Capital Management Inc. raised its position in shares of Nevro by 2,245.0% in the first quarter. Victory Capital Management Inc. now owns 2,345 shares of the medical equipment provider’s stock worth $203,000 after acquiring an additional 2,245 shares during the period.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Featured Story: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.